Express News | Alnylam Pharmaceuticals Inc : Jefferies Raises Target Price to $294 From $243
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Alnylam Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Alnylam Pharmaceuticals Price Target Raised to $220.00/Share From $150.00 by Cantor Fitzgerald
Express News | Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $220
Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
Press Release: Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,851,273, According to a Recent SEC Filing
Alnylam Pharmaceuticals (NASDAQ:ALNY) Rallies 3.8% This Week, Taking Five-year Gains to 246%
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 67% Share Price Surge Not Quite Adding Up
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $255
Alnylam Pharmaceuticals And Two More Value Stocks On US Exchange Estimated To Be Trading Below Intrinsic Value
BMO Sees BMRN, LEGN, SLN as Attractive M&A Targets
Express News | Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $357
Express News | Alnylam Pharmaceuticals Shares up 1.1% After Canaccord Genuity Raises PT on Stock
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $357
Express News | Alnylam Pharmaceuticals Inc : Canaccord Genuity Raises Target Price to $357 From $283